en · de · es · fr · pt
sr9009-notes.peptides6088.com › News › Analytical Detection And Laboratory Handling — Quick Reference

Analytical Detection And Laboratory Handling — Quick Reference

By Editorial Desk · published 2026-04-14 · last reviewed 2026-05-26 · News

The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.

Analytical Detection and Laboratory Handling

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Sr9009 at a glance

PropertyValueNotes
AppearanceOff-white to pale yellow solidVisual description varies with purity and source
SolubilitySoluble in DMSO and ethanol; poorly soluble in waterOrganic stock solutions are common in research
Typical storage-20 °C, desiccated, protected from lightAvoid repeated freeze-thaw cycles
Typical analytical methodLC-MS or HPLC-UVReference standards are needed for quantification
Molar massApproximately 437.9 g/molCalculated from the reported free-base formula

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Related pages on this site

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Regulation, Testing, and Storage

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Background from the literature

In 1948, Lloyd Valberg participated in the 1948 Summer Olympics in London, which made him the first Singaporean to participate in the Olympic Games. The development of private sports and recreation clubs began in the 19th century colonial Singapore, with clubs founded during this time including the Cricket Club, the Singapore Recreation Club, the Singapore Swimming Club, and the Hollandse Club. Weightlifter Tan Howe Liang was Singapore's first Olympic medalist, winning a silver at the 1960 Rome Games. Singapore hosted the inaugural 2010 Summer Youth Olympics, in which 3,600 athletes from 204 nations competed in 26 sports. Indoor and water sports are some of the most popular sports in Singapore. At the 2016 Rio Olympics, Joseph Schooling won Singapore's first Olympic gold medal, claiming the 100-metre butterfly in a new Olympic record time of 50.39 seconds. Singapore sailors have had success on the international stage, with their Optimist team being considered among the best in the world. Despite its size, the country has dominated swim meets in the Southeast Asia Games. Its men's water polo team won the SEA Games gold medal for the 27th time in 2017, continuing Singapore sport's longest winning streak. At the 2024 Paris Olympics, Max Maeder won Singapore's first Olympic medal in sailing, achieving bronze at the Men's Formula Kite on National Day. At 17, he was also Singapore's youngest Olympic medalist. Singapore's women's table tennis team were silver medalists at the 2008 Beijing Olympics.

Mylodontids are the only ground sloths confirmed to have osteoderms embedded within their skin, though osteoderms were only present in a handful of genera (Mylodon, Paramylodon and Glossotherium) and absent in others.

=== Shiley defective heart valves settlement (1994) === Pfizer purchased Shiley in 1979, at the onset of its Convexo-Concave valve ordeal, involving the Bjork–Shiley valve. Approximately 500 people died when defective heart valves fractured and, in 1994, Pfizer agreed to pay $10.75 million to settle claims by the United States Department of Justice that the company lied to get approval for the valves.

The Popular Front for the Liberation of Bahrain (Arabic: الجبهة الشعبية لتحرير البحرين, romanized: al-Jabha ash-Shaʿbiyya li-Taḥrīr al-Baḥrayn) was an underground political party in Bahrain with origins in the Arab Nationalist Movement. Its members were inclined towards the leftist Marxist trend within the Arab Nationalist Movement. It was created after the Popular Front for the Liberation of Oman and the Arabian Gulf was reconstituted into two separate organizations as the Popular Front for the Liberation of Oman and the Popular Front for the Liberation of Bahrain. Several PFLB members participated in the 1963 to 1976 Dhofar Rebellion in Oman. In 2000, PFLB members established the National Democratic Action Society, the first officially licensed political organization in any of the Arab states of the Persian Gulf. The PFLB was replaced by the NDAS.

The reaction proceeds in two stages. The first protein component, called RebP, is an oxidase which contains heme and uses oxygen and nicotinamide adenine dinucleotide (NADH) to form the new aromatic bond between the indole components, making a six-membered ring. The RebP component then acts with a flavin-dependent partner called RebC to remove the two carboxylic acid groups by oxidative decarboxylation.

Sources: en.wikipedia.org

Further detail

=== Nana Mary === Nana Mary is played by Shelley Winters. Nana Mary is Beverly's mother and Roseanne and Jackie's grandmother, and first appears at a family barbecue in season three. She has another daughter named Sonya. She makes several appearances from season three onward, mostly during family occasions. She is a brash but caring, outspoken, lovable retiree who gambles with her grandchildren. Unlike Bev, she is popular with the family. She also disagrees with Bev in certain situations, such as siding with Jackie when Bev urges her to marry Fred, and revealing that she had two abortions, upsetting Bev. She outsmarts Bev and torments her, much to the amusement of Roseanne and Jackie, who usually endure the same treatment from Bev. Her character is often a comic relief for the family, as well as offering a balance between Roseanne and Jackie's relationship with their mother, and Bev's relationship with Nana Mary. She was promiscuous in her youth and claims that as a globe-trotting free spirit she knew Pablo Picasso, Louis Armstrong, Ernest Hemingway, Fidel Castro, and Meyer Lansky, among others. Mary had Bev with another man before marrying her deceased husband, Marvin. She tells Bev she was very young when she gave birth, admits to not knowing who the father is, and avoided the subject until Bev demanded to finally know. Mary is a fan of a local radio call-in show that revolves around sex: "If I don't call, they worry," she claims.

The Jardin des Plantes is the home of the main galleries of the MNHN, and a division of the museum, which was born there. The garden was founded by Louis XIII 1635 as the Royal Garden of medicinal plants, under the direction of the royal physician. In the early 18th century, the chateau of the gardens was enlarged to house the collections of the royal pharmacist. In 1729, this collection was broadened into the Cabinet of Natural History, destined to receive the Royal collections dedicated to zoology and mineralogy. New plants and animal species were collected from around the world, examined, illustrated, classified, named and described in publications which were circulated across Europe and to America. An amphitheatre was constructed in the garden in 1787 to provide a venue for lectures and classes on the new discoveries. New greenhouses were built beginning in 1788, and the size of the gardens was doubled. The gardens served as the laboratory of scientists including Jean Baptiste Lamarck, author of the earliest theory of evolution, and were a base for major scientific expeditions by Nicolas Baudin, Alexander von Humboldt, Jules Dumont d'Urville and others throughout the 18th and 19th century. The gardens today include a large formal garden planted in geometric designs; and two enormous greenhouses, keeping tropical plants at a steady temperature of 22 degrees Celsius. The Alpine gardens present plants coming from Corsica, the Caucasus, North American and the Himalaya. The gardens of the School of Botany contain 3,800 species of plants, displayed by genre and family.

=== Other ventures === Around 2013, Newell co-founded and funded Foundry10, an educational research organization. In 2018, Newell donated $20 million to the American artificial intelligence company OpenAI and acted as an informal advisor. In 2022, with Philip Sabes, Newell co-founded the neuroscience company Starfish Neuroscience to develop neural interfaces. In May 2025, Starfish announced that their first chip would be released late that year. Newell is the owner of the marine research organization Inkfish, which owns several ships and submarines. In November 2022, Inkfish purchased the Hadal Exploration System, a private deep-sea exploration platform, from the undersea explorer Victor Vescovo. In August 2025, Newell acquired the privately owned yacht manufacturer Oceanco.

Spironolactone has been found to decrease the bioavailability of high doses of oral estradiol. Although widely employed, the use of spironolactone as an antiandrogen in transgender women has recently been questioned due to the various shortcomings of the medication for such purposes. Cyproterone acetate is an antiandrogen and progestin which is used in the treatment of numerous androgen-dependent conditions and is also used as a progestogen in birth control pills. It works primarily as an antigonadotropin, secondarily to its potent progestogenic activity, and strongly suppresses gonadal androgen production. Cyproterone acetate at a dosage of 5 to 10 mg/day has been found to lower testosterone levels in men by about 50 to 70%, while a dosage of 100 mg/day has been found to lower testosterone levels in men by about 75%. The combination of 25 mg/day cyproterone acetate and a moderate dosage of estradiol has been found to suppress testosterone levels in transgender women by about 95%. In combination with estrogen, 10, 25, and 50 mg/day cyproterone acetate have all shown the same degree of testosterone suppression. In addition to its actions as an antigonadotropin, cyproterone acetate is an androgen receptor antagonist. However, this action is relatively insignificant at low dosages, and is more important at the high doses of cyproterone acetate that are used in the treatment of prostate cancer (100–300 mg/day). Cyproterone acetate can cause elevated liver enzymes and liver damage, including liver failure.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

What is known about its stability?

The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.

Why does solubility matter?

Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network